Ozontherapie zur Behandlung des Post-Covid-Syndroms

Zusammenfassung

Das Post-Covid-Syndrom stellt eine komplexe Erkrankung dar, die allerdings durch einen integrativen Behandlungsansatz in der kombinierten Anwendung mit individuellen orthomolekularen Substanzen erfolgreich therapiert werden kann. Wichtig ist eine Aufklärung über die Hintergründe der Symptome und die Notwendigkeit einer integrativen Behandlung zu einem möglichst frühen Zeitpunkt. Beim Epstein-Barr-Virus sind ähnliche Verläufe bekannt, ohne dass dies zu entsprechenden medialen angsterzeugenden Darstellungen führt. Im Rahmen eines multimodalen Behandlungsansatzes, gestützt auf eine individuelle Labordiagnostik, stellt die Ozontherapie eine wichtige Basismaßnahme dar. Die Verträglichkeit ist sehr gut und zeigt im Sinne der Regulationsmedizin modulatorische Effekte auf immunologische Faktoren. Weiterhin werden antioxidative Kapazitäten verbessert.

Abstract

The post-COVID syndrome is a complex disease. However, it can be treated successfully by an integrative treatment approach in combined application with individual orthomolecular substances. It is important to provide information about the background of the symptoms as well as the need for an integrative treatment at the earliest possible stage. Similar courses are known for the Epstein-Barr virus, but this does not lead to corresponding scaremongering portrayals in the media. Within the framework of a multimodal treatment approach, supported by an individual laboratory diagnostics, the ozone therapy represents an important basic measure. It is very well tolerated and shows modulatory effects on immunological factors in the sense of regulatory medicine. Furthermore, antioxidant capacities are improved.

Schlüsselwörter

Ozontherapie - Post-Covid-Syndrom - Long Covid - Corona-Pandemie - Covid-19 - Fatigue

Keywords

Ozone therapy - post-COVID syndrome - Long COVID - corona pandemic - COVID-19 - fatigue

Publication History

Article published online:
12 October 2022

• Literatur

• 1 WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. 06.10.2021 Im Internet: Accessed August 30, 2022 at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
• 2 Tirelli U, Taibi R, Chirumbolo S. Post COVID syndrome: A new challenge for medicine. Eur Rev Med Pharmacol Sci 2021; 25: 4422-4425
• 3 Rubin MB. The history of ozone. The Schönbein Period, 1839–1868. Bull Hist Chem. 2001 26. Im Internet: Accessed August 30, 2022 at: http://www.scs.illinois.edu/~mainzv/HIST/awards/OPA%20Papers/2001-Rubin.pdf
• 4 Bocci VA. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 2006; 37: 425-435
• 5 European Cooperation of Medical Ozone Societies EUROCOOP (Ärztliche Gesellschaft für Ozon-Anwendung in Prävention und Therapie). Information for patients. Im Internet: Accessed August 30, 2022 at: http://www.ozongesellschaft.de/information_for_patients_60.htm
• 6 International Scientific Committee of Ozonetherapy (ISCO3). Ozone therapy and its scientific foundations. Madrid: 2012. Im Internet: https://isco3.org/
• 7 Tirelli U, Franzini M, Valdenassi L. et al. Patients with myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) greatly improved fatigue symptoms when treated with oxygen-ozone autohemotherapy. J Clin Med 2022; 11: 29
• 8 Schwartz A, Martínez-Sánchez G, de Lucía AM. et al. Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study. J Pharm Pharmacogn Res 2021; 9 (02) 126-142
• 9 Izadi M, Cegolon L, Javanbakht M. et al. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review. Int Immunopharmacol 2021; 92: 107307
• 10 Tirelli U, Franzini M, Valdenassi L. et al. Fatigue in post-acute sequelae of SARS-CoV-2 (PASC) treated with oxygen-ozone autohemotherapy – preliminary results on 100 patients. Eur Rev Med Pharmacol Sci 2021; 25 (18) 5871-5875
• 11 Chacko BK, Kramer PA, Ravi S. et al. The Bioenergetic Health Index: A new concept in mitochondrial translational research. Clin Sci (Lond) 2014; 127 (06) 367-373